Member
2 Awards

CorNeat Vision


CorNeat Vision is dedicated to developing innovative biomimetic medical solutions aimed at addressing unmet medical needs across various therapeutic fields. Their mission is to harness biomimicry to improve health and equality worldwide, focusing on creating permanent, synthetic implants that integrate seamlessly with human tissue.

Industries

health-care
medical
medical-device
wellness

Nr. of Employees

small (1-50)

CorNeat Vision

4 HaSheizaf St. Ra'anana, Israel

Awards

CorNeat gPatch: A novel approach to gingival guided tissue and bone regeneration (GTR, GBR) using EverMatrix™ technology

Funding (ceiling)

$2,240,535

Award Year

2022

Military Prototype Advancement Initiative (MPAI)

CorNeat KPro: A synthetic self-integrating artificial cornea: Accelerating FDA clearance for combat related corneal blindness indications

Funding (ceiling)

$2,192,848.46

Award Year

2023


Patents

Keratoprosthesis devices and kits and surgical methods of their use

2025-07-22 • US-12364591-B2

View Details

Keratoprosthesis and uses thereof

2022-01-04 • US-11213382-B2

View Details

Keratoprosthesis and uses thereof

2020-06-02 • US-10667902-B2

View Details

Products

Artificial cornea (synthetic keratoprosthesis)

A biomimetic, fully synthetic corneal implant engineered to integrate permanently with the eye wall and restore optical function without donor tissue.

Synthetic scleral reinforcement patch (non-degradable)

Thin, sterile, non-degradable synthetic tissue patch intended to reinforce the sclera and reconstruct the ocular surface as an alternative to tissue grafts.

Glaucoma drainage device for refractory cases

A drainage implant intended to extend minimally invasive glaucoma surgery options for severe or refractory patients, designed to be concealed beneath tissue and integrated with surrounding structures.

Expertise Areas

  • Biomaterials and tissue integration
  • Ophthalmic implant design and development
  • Preclinical safety and biocompatibility testing
  • First-in-human clinical trial execution
  • Show More (4)

Key Technologies

  • Tissue-integrating synthetic biomaterials (non-degradable polymer matrices)
  • Synthetic keratoprosthesis (artificial cornea)
  • Synthetic scleral reinforcement membranes
  • Glaucoma drainage device design
  • Show More (3)

Key People

Gilad Litvin, MD

Co-Founder, Chairman, Chief Medical Officer

LinkedIn

Tzvika Fisher

Chief Operating Officer

LinkedIn

Ido Klein

Director of Clinical & Pre-Clinical Studies

LinkedIn

Eli Aharoni

Chief Executive Officer, VP of Research and Development

LinkedIn

Patricia Assouline

Director of Project Management

LinkedIn

News & Updates

Come and visit our booth at the American Glaucoma Society's annual meeting.

Our synthetic cornea, the CorNeat KPro, is featured in the Corneal Physician magazine!

A profile on our CEO and VP R&D, Almog Aley-Raz.

The CorNeat EverPatch, our synthetic tissue patch, hits the newsstands!

The CorNeat EverPatch received FDA 510(k) clearance in June 2023, marking a significant milestone for the product.

The CorNeat KPro successfully completed its First-in-Human trial, allowing corneally blind patients to regain their sight and independence.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.